GENETIC ANALYSIS NK -60 (F:8V8) — Market Cap & Net Worth
Market Cap & Net Worth: GENETIC ANALYSIS NK -60 (8V8)
GENETIC ANALYSIS NK -60 (F:8V8) has a market capitalization of $2.85 Million (€2.43 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #29553 globally and #2575 in its home market, demonstrating a -1.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENETIC ANALYSIS NK -60's stock price €0.04 by its total outstanding shares 69087041 (69.09 Million). Review 8V8 total debt and obligations to assess the company's total debt and financial obligations.
GENETIC ANALYSIS NK -60 Market Cap History: 2021 to 2026
GENETIC ANALYSIS NK -60's market capitalization history from 2021 to 2026. Data shows change from $48.70 Million to $3.13 Million (-48.88% CAGR).
GENETIC ANALYSIS NK -60 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENETIC ANALYSIS NK -60's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
GENETIC ANALYSIS NK -60's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $48.70 Million | $6.80 Million | -$29.01 Million | 7.16x | N/A |
| 2022 | $13.38 Million | $11.16 Million | -$28.27 Million | 1.20x | N/A |
| 2023 | $4.35 Million | $14.15 Million | -$23.82 Million | 0.31x | N/A |
| 2024 | $1.83 Million | $15.89 Million | -$14.77 Million | 0.11x | N/A |
| 2025 | $3.43 Million | $16.71 Million | -$11.41 Million | 0.21x | N/A |
Competitor Companies of 8V8 by Market Capitalization
Companies near GENETIC ANALYSIS NK -60 in the global market cap rankings as of June 19, 2026.
Key companies related to GENETIC ANALYSIS NK -60 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $174.56 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.14 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.56 Billion | $464.61 |
| #189 | Danaher Corporation | NYSE:DHR | $125.14 Billion | $177.17 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $562.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
GENETIC ANALYSIS NK -60 Historical Marketcap From 2021 to 2026
Between 2021 and today, GENETIC ANALYSIS NK -60's market cap moved from $48.70 Million to $ 3.13 Million, with a yearly change of -48.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.13 Million | -8.71% |
| 2025 | €3.43 Million | +88.05% |
| 2024 | €1.83 Million | -57.99% |
| 2023 | €4.35 Million | -67.51% |
| 2022 | €13.38 Million | -72.54% |
| 2021 | €48.70 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of GENETIC ANALYSIS NK -60 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.85 Million USD |
| MoneyControl | $2.85 Million USD |
| MarketWatch | $2.85 Million USD |
| marketcap.company | $2.85 Million USD |
| Reuters | $2.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more